title: Lung transplantation in patients with cystic fibrosis.
abstract: Cystic fibrosis (CF) an autosomal recessive genetic disorder, affects many organs. The great majority of deaths occur due to respiratory failure after many years of chronic pulmonary infection. Despite recent progress in early detection by studies of genetic mutations and better understanding to treat nutritional and infectious states, lung transplantation is the CF treatment for most advanced cases. According to the International Society for Heart and Lung Transplantation (ISHLT) data, CF is the third most common reason for lung transplantation (16.8%) showing the best survival rate (60% at 5 years). We have described our experience in lung transplantation of CF patients between January 2000 and December 2011, reviewing medical charts of these patients were for gender, age, body mass index (BMI), comorbidities, disease duration, previous sputum gram stain, ischemic time, incidence of severe primary graft dysfunction (PGD Grade 3), intensive care unit (ICU) length of stay, and Kaplan-Meier survival. Among 150 lung transplantation, the 30 CF patients (20%) represented the second most common cause. The average age was 27.4 ± 9.2 years, with a slight predominance of males (n = 16; 53.3%). The average BMI was 18.9 ± 2.6. Most patients (60%) had pancreatic exocrine dysfunction. Also, 83.3% of patients showed a positive sputum culture for Pseudomonas, while Burkholderia cepacia was identified in only 4 patients (13.3%). The average time of the disease was 20.8 ± 9.7 years. All transplantation were bilateral with an average ischemic time of 472 ± 98.3 minutes and ICU length of stay of 9.9 ± 6.3 days. The survival rates at 1 and 5 years were 92% and 77%, respectively, corresponding to the best outcomes among underlying diseases, comparable with other worldwide series and better than the ISHLT reports. CF, the second most common cause for lung transplantation among our cases, showed the best survival rate among all causes. Our survival rate was comparable with other reports.
authors.affiliation: Lung Transplant Group, Thoracic Surgery Division of Heart Institute (InCor) do Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil. marcos.samano@incor.usp.br
authors.forename: M N
authors.initials: MN
authors.lastname: Samano
authors.forename: P M
authors.initials: PM
authors.lastname: Pêgo-Fernandes
authors.forename: A K
authors.initials: AK
authors.lastname: Fonseca Ribeiro
authors.forename: K
authors.initials: K
authors.lastname: Turaça
authors.forename: L G
authors.initials: LG
authors.lastname: Abdalla
authors.forename: L M
authors.initials: LM
authors.lastname: Fernandes
authors.forename: A T
authors.initials: AT
authors.lastname: Correia
authors.forename: F B
authors.initials: FB
authors.lastname: Jatene
mesh_terms: D000293:Adolescent; D000328:Adult; D003550:Cystic Fibrosis / Q000601:surgery*; D005260:Female; D006801:Humans; D016040:Lung Transplantation; D008297:Male; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult